ZYUS Life Sciences receives second US pain management patent

Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital

Alebund Pharmaceuticals completes AP301 Phase III clinical trial patient enrolment for hyperphosphataemia

Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education

Atossa Therapeutics' (Z)-endoxifen receives FDA Rare Pediatric Disease designation for McCune-Albright Syndrome

Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation

Sprout Pharmaceuticals named one of TIME's most influential health and life sciences companies of 2026

European Commission clears first pertuzumab biosimilar in Europe

Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence

C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance

GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation

Johnson & Johnson IMAAVY (nipocalimab-aahu) granted FDA Priority Review as potential treatment for wAIHA

Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove

Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA

Novartis secures European approval for remibrutinib in chronic spontaneous urticaria